Gilead Sciences Inc (GILD): Today's Featured Health Care Winner

Gilead ( GILD) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.1%. By the end of trading, Gilead rose 51 cents (1%) to $51.17 on light volume. Throughout the day, 3.5 million shares of Gilead exchanged hands as compared to its average daily volume of 6.1 million shares. The stock ranged in a price between $50.51-$51.26 after having opened the day at $50.55 as compared to the previous trading day's close of $50.66. Other companies within the Health Care sector that increased today were: Opexa Therapeutics ( OPXA), up 86%, IsoRay ( ISR), up 32.4%, Cormedix ( CRMD), up 19.1%, and Affymax ( AFFY), up 15.8%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases worldwide. Gilead has a market cap of $38.37 billion and is part of the drugs industry. The company has a P/E ratio of 15.3, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are up 23.8% year to date as of the close of trading on Thursday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, solid stock price performance, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, K-V Pharmaceutical Company ( KV.B), down 21.2%, Reliv' International ( RELV), down 13.6%, American Caresource Holdings ( ANCI), down 12.8%, and Ampio Pharmaceuticals ( AMPE), down 12.3%, were all losers within the health care sector with Incyte ( INCY) being today's health care sector loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).